- Fabbri L, Barnes P, Buist A, Calverley P, Fukuchi Y, MacNee W, Pauwels R, Rabe K, Rodriguez-Roisin R, Zielinki I. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: Executive Summary. National Heart, Lung, and Blood Institute–World Health Organization (NHLBI–WHO) workshop report 2003. Available at http://www.goldcopd.com/revised_es.pdf; accessed January 5, 2004.
- Panning CA, DeBisschop M. Tiotropium: an inhaled, long-acting anticholinergic drug for chronic obstructive pulmonary disease. Pharmacotherapy 2003;23: 183–189.
- Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, Menjoge SS, Serby CW, Witek T Jr. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19: 217–224.
- Barnes PJ. The pharmacological properties of tiotropium. Chest 2000;117 (2 Suppl): 63S–66S.
- Spiriva® (tiotropium) for oral inhalation use [product information]. Boehringer Ingelheim and Pfizer, Inc, January 2004. Available at http://www.bidocs.com/renetnt:/Prescribing%20Information/PIs/Spiriva/Spiriva.pdf?DMW_FORMAT=pdf; accessed February 10, 2004.
- Hutchison TA, Shahan DR, eds. DRUGDEX® System, MICROMEDEX, Inc., Greenwood Village, Colorado (edition expires 03/04).
- Littner MR, Ilowite JS, Tashkin DP, Friedman M, Serby CW, Menjoge SS, Witek TJ Jr. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161 (4 Pt 1): 1136–1142.
- Casaburi R, Briggs DD Jr, Donohue JF, Serby CW, Menjoge SS, Witek TJ Jr. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group. Chest 2000;118: 1294–1302.
- Tashkin D, Kesten S. Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. Chest 2003;123: 1441–1449.
- van Noord JA, Bantje TA, Eland ME, Korducki L, Cornelissen PJ. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax 2000;55: 289–294.
- Vincken W, van Noord JA, Greefhorst AP, Bantje TA, Kesten S, Korducki L, Cornelissen PJ; Dutch/Belgian Tiotropium Study Group. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002;19: 209–216.
- Donohue JF, van Noord JA, Bateman ED, Langley SJ, Lee A, Witek TJ Jr, Kesten S, Towse L. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002;122: 47–55.
- Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003;58: 399–404.
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 17, 2004 - Issue 3